Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?

2026-02-25 04:27:52

Abstract generation in progress

Abbott Laboratories recently increased its quarterly dividend, reaching 13 consecutive years of dividend growth, maintaining its Dividend Aristocrat status. While strong in medical devices and innovation, the company faces challenges including a Class I recall for its FreeStyle Libre and weakness in its nutrition segment. Despite these headwinds and a moderately high payout ratio, Abbott’s management remains committed to dividend growth, supported by adequate cash flow and strategic acquisitions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.